Cogent Biosciences annual capital expenditures (capex)
2017
2018
2019
2021
2022
2023
2024
2025
Cogent Biosciences Capital Expenditures (CapEx) Growth & History (COGT)
Cogent Biosciences's capital expenditures (capex) was $1.6M for fiscal 2025.
View full Cogent Biosciences company overviewCogent Biosciences annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.6M | $981,000 | +171.20% |
| 2024 | 2024-12-31 | $573,000 | −$2.2M | −79.51% |
| 2023 | 2023-12-31 | $2.8M | −$4.1M | −59.26% |
| 2022 | 2022-12-31 | $6.9M | $5.1M | +299.24% |
| 2021 | 2021-12-31 | $1.7M | — | — |
| 2019 | 2019-12-31 | $33,000 | −$516,000 | −93.99% |
| 2018 | 2018-12-31 | $549,000 | −$363,000 | −39.80% |
| 2017 | 2017-12-31 | $912,000 | — | — |
Cogent Biosciences quarterly capital expenditures (capex)
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $370,000 | $239,000 | +182.44% |
| Q1 2026 | 2026-03-31 | $449,000 | −$98,000 | −17.92% |
| Q4 2025 | 2025-12-31 | $811,000 | $736,000 | +981.33% |
| Q3 2025 | 2025-09-30 | $65,000 | −$215,000 | −76.79% |
| Q2 2025 | 2025-06-30 | $131,000 | −$17,000 | −11.49% |
| Q1 2025 | 2025-03-31 | $547,000 | $477,000 | +681.43% |
| Q4 2024 | 2024-12-31 | $75,000 | −$240,000 | −76.19% |
| Q3 2024 | 2024-09-30 | $280,000 | $159,000 | +131.40% |
| Q2 2024 | 2024-06-30 | $148,000 | −$1.1M | −88.23% |
| Q1 2024 | 2024-03-31 | $70,000 | −$1.0M | −93.65% |
| Q4 2023 | 2023-12-31 | $315,000 | −$1.7M | −83.99% |
| Q3 2023 | 2023-09-30 | $121,000 | −$3.2M | −96.35% |
| Q2 2023 | 2023-06-30 | $1.3M | $113,000 | +9.88% |
| Q1 2023 | 2023-03-31 | $1.1M | $662,000 | +150.11% |
| Q4 2022 | 2022-12-31 | $2.0M | — | — |
| Q3 2022 | 2022-09-30 | $3.3M | $2.1M | +184.69% |
| Q2 2022 | 2022-06-30 | $1.1M | — | — |
| Q1 2022 | 2022-03-31 | $441,000 | — | — |
| Q3 2021 | 2021-09-30 | $1.2M | — | — |
| Q4 2019 | 2019-12-31 | $13,000 | $13,000 | — |
| Q3 2019 | 2019-09-30 | $22,000 | −$64,000 | −74.42% |
| Q2 2019 | 2019-06-30 | $0 | −$388,000 | — |
| Q1 2019 | 2019-03-31 | $42,000 | −$33,000 | −44.00% |
| Q4 2018 | 2018-12-31 | $0 | −$100,000 | — |
| Q3 2018 | 2018-09-30 | $86,000 | −$189,000 | −68.73% |
| Q2 2018 | 2018-06-30 | $388,000 | $171,000 | +78.80% |
| Q1 2018 | 2018-03-31 | $75,000 | −$245,000 | −76.56% |
| Q4 2017 | 2017-12-31 | $100,000 | — | — |
| Q3 2017 | 2017-09-30 | $275,000 | — | — |
| Q2 2017 | 2017-06-30 | $217,000 | — | — |
| Q1 2017 | 2017-03-31 | $320,000 | — | — |
Cogent Biosciences capital expenditures (capex) trends
Between the periods ended 2017-12-31 and 2025-12-31, Cogent Biosciences's capital expenditures (capex) increased from $912,000 to $1.6M, a change of $642,000. The latest reported quarter, Q2 2026, shows $370,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cogent Biosciences source filings ↗